Tag Archives: 爱上海WY


Fiddler’s Samantha Massell on Shower Songs, Late-Night Snacks & More

first_img Related Shows View Comments Age: 25Hometown: New York, NYCurrent Role: A standout performance as Hodel, Tevye’s second oldest daughter, who falls for a radical, young man in Broadway’s new revival of Fiddler on the Roof. Stage and Screen Cred: Massell has appeared on the New York stage in the ensemble of Broadway’s La Boheme and two shows at Encores! (Little Me and It’s A Bird…It’s A Plane…It’s Superman). Her regional credits include The Hunchback of Notre Dame at both La Jolla and the Paper Mill Playhouse, and Aladdin, Into the Woods and Bye Bye Birdie all at the MUNY. Fiddler on the Roof Show Closed This production ended its run on Dec. 31, 2016last_img read more


FDA approvals clear way for flu vaccine marketing

first_imgEditor’s note: This story was updated Aug 7 to include information about the start of influenza vaccine shipments by Novartis.Aug 6, 2008 (CIDRAP News) – The six companies that make influenza vaccine for the US market have won federal approval for their version of this year’s vaccine, in which all three flu strains used in last year’s product have been replaced, the Food and Drug Administration (FDA) announced yesterday.The FDA announcement clears the way for marketing of the vaccines. At least three vaccine makers have begun shipping vaccine to distributors and providers, according to recent company announcements.The six manufacturers and their vaccines are CSL Limited, Afluria; GlaoxSmithKline Biologicals, Fluarix; ID Biomedical Corp. of Quebec (a unit of GlaxoSmithKline), FluLaval; MedImmune, FluMist; Novartis Vaccines and Diagnostics, Fluvirin; and Sanofi Pasteur, Fluzone.In the wake of a relatively poor match between the vaccine and circulating flu strains last season, experts at the World Health Organization and the FDA in February recommended changing all three strains of virus used in the vaccine. In most years only one or two of the three strains are changed.”One of the biggest challenges in the fight against influenza is producing new vaccines every year,” Jesse Goodman, MD, MPH, director of the FDA’s Center for Biologics Evaluation and Research, said in a news release. “There is no other instance where new vaccines must be made every year.”Two of the three strains in the 2008-09 vaccine are included in vaccines now being used in the Southern Hemisphere, where the flu season is under way, the FDA noted.The decision to change all three strains in the vaccine had generated some concern about possible production delays or low yields of the viruses, which are grown in eggs. But Curtis Allen, a spokesman for the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC) in Atlanta, said today he hasn’t heard of any problems growing the strains.”Vaccine production is always fraught with risk and anywhere along the line things can go wrong, but so far they have not, and we’re looking forward to a season with adequate supplies of vaccine,” Allen told CIDRAP News.At a meeting in May, manufacturers estimated they would produce a record total of 143 million to 146 million doses of flu vaccine for the US market this year. Allen said the estimates of vaccine production have not changed since then. Last year 140 million doses were produced.Allen listed the manufacturers’ production estimates as follows: Sanofi Pasteur, 50 million doses; GlaxoSmithKline (including ID Biomedical), 35 million to 38 million; MedImmune, 12 million; Novartis, 40 million; and CSL, 6 million.Sanofi announced Aug 1 that it had begun shipping the first 1.3 million doses of Fluzone. “Vaccine shipments to healthcare providers and to the [CDC] for distribution through the Vaccines for Children Program will continue through the fall and are planned to be completed in October,” the company said in a news release.The statement indicated that replacing all three strains of virus has not caused any major production problems.”Introduction of three new strains for the influenza vaccine was unprecedented and could have resulted in a low yield or delay given our tight production timeline. Despite these challenges, we are pleased that once again Sanofi Pasteur has demonstrated its reliability in supplying Fluzone vaccine to the US market,” said Wayne Pisano, the company’s president and chief executive officer, in the news release.MedImmune announced yesterday that shipments of FluMist, a nasal-spray vaccine that uses a weakened form of live virus, had begun on Jul 31. In a news release, the company affirmed that it plans to produce about 12 million doses, a record number.FluMist will be available at some retail pharmacies and supermarkets and in nearly 200 school-based vaccination programs and university health centers, the company said. In addition, the federal government, as in past years, is buying some doses for use in military personnel, officials said.Novartis announced Aug 7 that it has begun shipping Fluvirin to US healthcare providers. The company said it expects to deliver 20 million doses by the end of September and aims to deliver the remaining 20 million by Oct 31. Officials said the company has added a second manufacturing facility, located in Rosia, Italy, to help supply flu vaccine earlier in the season. The firm’s other facility is in Liverpool, England.”Despite the new composition [of the vaccine], Novartis made sure we were able to deliver a timely and robust supply of influenza vaccine this year,” said Rajiv De Silva, president of Novartis Vaccines in the US, in a news release.This is the first year the CDC is formally recommending flu shots for school-age children, adding about 30 million people to the ranks of those targeted for vaccination. Allen said the total number of those targeted for vaccination—including people at risk for serious flu complications and their close contacts—is about 258 million, or roughly 84% of the population.See also: Aug 5 FDA news releasehttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116933.htmFDA page with chart of vaccine lot releaseshttp://www.fda.gov/cber/flu/flu2008.htmAug 4 MedImmune news releaseAug 1 Sanofi Pasteur news releasehttp://www.vaccineplace.com/docs/first_shipment_release.pdfMay 13 CIDRAP News story “Flu experts try to ensure record vaccine doses get used”Feb 22 CIDRAP News story “FDA endorses overhaul for 2008-09 flu vaccine”last_img read more


David Seaman: Petr Cech solves Arsenal’s goalkeeping problem

first_img Press Association The 33-year-old was Arsene Wenger’s only signing during a quiet transfer window at the Emirates Stadium as the Arsenal boss looked to find a goalkeeper he could fully trust. Cech, who won 13 major honours during an 11-year stint at Chelsea, moved across London and has played every competitive game since. David Seaman believes the signing of Petr Cech could give Arsenal the consistency they need to mount a sustained title challenge. He may sit out Wednesday night’s third round Capital One Cup clash against fierce local rivals Tottenham, but he has been backed by former Gunners number one Seaman as a man who can turn the club into bona fide championship contenders. “It is a problem solved for Arsene,” Seaman told Press Association Sport. “You have got a goalkeeper there with great quality, great experience and who commands immediate respect from the Arsenal players for what he has done in the game. “(David) Ospina has done well and is a little unfortunate to find himself as number two – Wojciech Szczesny has shown inconsistency and you can’t do that as Arsenal goalkeeper. “With Cech you have just got quality. The consistency helps sustain a challenge, it helps the confidence of the defence – they know you’re not going to be making mistakes and being rash in games. “That is what you get with Petr Cech, he won’t make many mistakes and he is already showing how good he is despite having a new back four in front of him.” Despite the addition of Cech, many Arsenal supporters were upset that the club did not bolster their outfield options – the only club in the top five European leagues not to do so. But Seaman trusts Wenger and thinks he may dip into the transfer market when the window reopens in the new year, using some of the cash reserve of £193.1m revealed last week by financial figures for Arsenal’s parent company. “I’m sure in the January window there will be movement, especially now the figures for how much Arsene has to spend have come out,” he added. “If they get to January in a strong positon, I’m sure he will strengthen again. “It is brave that he has not listened to everyone and gone and spent money but he is in the same mould as Sir Alex Ferguson – so many people think they know more than Wenger but I’m sorry, they don’t. He knows the club better than anyone and knows what they need.” As well as the likelihood being Cech will be rested at White Hart Lane, midfielder Santi Cazorla will serve a suspension for the red card he picked up in Saturday’s controversial 2-0 defeat at Cech’s former side Chelsea. There is also the prospect that Tottenham head coach Mauricio Pochettino will rotate his squad, meaning Michel Vorm could start ahead of first-choice stopper Hugo Lloris. France international Lloris was linked with a move away from Spurs in the summer but Seaman is a big fan of Tottenham’s new skipper. “He is really good. He is top, top quality,” he said. “He makes saves that you don’t expect him to make. I know he is not a big goalkeeper but he makes the saves, you see the gaps but he gets there. “He is a top quality goalie. It was all set to move around if David De Gea looked set to leave Man United. I’m sure a goalkeeper of that quality will be wanting to contend for trophies.” :: David Seaman was speaking on behalf of The Football League and Capital One – the credit card in your corner. Visit facebook.com/CapitalOneUK last_img read more